Keywords: Therapeutic, cancer, myeloma, melanoma, lung, breast, histone deacetylase, HDAC, rapamycin, mTOR
The Lung Cancer Biomarkers Group of the National Cancer Institute (NCI) seeks parties interested in collaborative research to further co-develop methods for selecting cancer patients for combination therapy.
Available for co-development is a novel gene signature of thirty-seven drug-responsive genes that links changes in gene expression to the clinically desirable outcome of improved overall survival. Expression of these genes has been linked to prognosis in several cancers, including, but not limited to: multiple myeloma, melanoma, and lung and breast cancers. Patients identified by this signature would be predicted to benefit from combined HDAC inhibitor/mTOR inhibitor therapy.
Potential Commercial Applications:
Development Stage: Pre-clinical, in vitro and in vivo animal data available.
Patent Status: U.S. Provisional Application No. 61/558,402 filed 10 Nov 2011
Contact: Please submit an information request form at http://techtransfer.cancer.gov or contact:
John D. Hewes, Ph.D.
Last updated: 06/28/2012